Profectus BioSciences Inc., and the Galveston National Laboratory (GNL) at the University of Texas Medical Branch at Galveston recently received a three-year, $8.5 million grant from the Department of the Army
The grant will support studies of the early steps of Ebola and Marburg vaccine development.
Profectus has developed VesiculoVax, a vaccine delivery system, to address disease indications where the rapid use of neutralizing antibodies is needed to protect against the viruses that cause hemorrhagic fevers."In light of the current outbreak of Ebola in Western Africa, we are grateful that the Department of the Army has recognized the potential of Profectus' VesiculoVax rVSV-vectored filovirus vaccine to counter biowarfare threats and Profectus BioSciences is confident it will also have application with regard to protecting civilians and military personnel against highly lethal emerging infectious diseases," Profectus Chief Scientific Officer John Eldridge said. "In studies conducted by the National Institutes of Health in nonhuman primates, the Profectus vaccine has been shown to provide rapid protection against hemorrhagic fever viruses such as Ebola and Marburg, and is the only vaccine to have demonstrated single-dose protection of monkeys against lethal challenge with low-passage Ebola and Marburg viruses. We remain committed to finding the means to move these treatment options into clinical evaluation as rapidly as possible."